You are here: Industry Insights > NASH

News List

Gannex Received China IND Approval of Its FXR Agonist ASC42 for NASH Indication prnasia
May 27, 2021
Gannex today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its drug candidate ASC42 to conduct clinical trials for NASH indication.
Dicerna Announces Boehringer Ingelheim’s Acceptance of Candidate for Development Under RNAi Research Collaboration and License Agreement americanpharmaceuticalreview
May 25, 2021
Dicerna announced that Boehringer Ingelheim has accepted a GalXC™ RNAi candidate for advancement under the existing agreement between the companies for the discovery and development of novel therapies for the treatment of chronic liver diseases.
CytoDyn and Biomm enter leronlimab supply agreement pharmaceutical-technology
April 09, 2021
CytoDyn (CYDY) and Biomm have signed an exclusive supply and distribution agreement that will enable the latter to market CCR5 antagonist leronlimab (PRO 140) in Brazil on receiving regulatory approval.
Sagimet Biosciences Receives Fast Track Designation from FDA for NASH Treatment americanpharmaceuticalreview
March 24, 2021
Sagimet Biosciences announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TVB-2640 for the treatment of patients with NASH.
Gilead, Novo Nordisk expand NASH clinical collaboration expresspharma
March 19, 2021
Gilead Sciences and Novo Nordisk announced that the companies have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH).
FASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH prnasia
March 09, 2021
Gannex Pharma Co., Ltd., a wholly-owned company of Ascletis Pharma Inc., and Sagimet Biosciences Inc. jointly announced today positive topline results from the China cohort of a Phase 2 randomized, placebo-controlled clinical trial of oral ...
Sciwind's Investigational New Drug Approved for NASH Trial prnasia
March 01, 2021
Hangzhou Sciwind Biosciences Co., Ltd. today announced that XW003, a potential candidate for the treatment of non-alcoholic steatohepatitis (NASH), has been approved by China NMPA for clinical trial.
Akero Initiates Phase 2b HARMONY Study of Efruxifermin for NASH americanpharmaceuticalreview
March 01, 2021
Akero Therapeutics has screened the first patients for its Phase 2b HARMONY study evaluating efruxifermin (EFX), the company's lead product candidate for the treatment of NASH.
Molecular Stethoscope Announces Publication of its NAFLD/NASH Study in the American Journal of Physiology - Gastrointestinal and Liver Physiology prnasia
February 23, 2021
Molecular Stethoscope, Inc., a precision medicine biotechnology company, announces publication of its human proof-of-concept study describing the stratification of NAFLD/NASH patients with clinically relevant and advanced liver fibrosis using the ...
Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-β Agonist ASC41 prnasia
February 22, 2021
Gannex announces the positive clinical results in overweight and obese subjects for ASC41, a liver-targeted prodrug. The active metabolite of ASC41 is a selective thyroid hormone receptor beta (THR-β) agonist.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page